TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38096102
Drug: MKI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MKI therapy (cohort 1)
Study: 38096102
Drug: Active surveillance
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active surveillance transitioning to MKI therapy (cohort 2)
Study: 38096105
Drug: Adjunctive systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive systemic corticosteroids
Study: 38096461
Drug: Obinutuzumab (G)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (G) plus chemotherapy (bendamustine, CHOP, or CVP)
Study: 38096461
Drug: Rituximab (R)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (R) plus chemotherapy (bendamustine, CHOP, or CVP)
Study: 38096462
Drug: PEG-L-Asparaginase (PEG-ASNASE,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-L-Asparaginase (PEG-ASNASE, 2,500 IU/sqm once a week × 4)
Study: 38096705
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin ± amoxicillin
Study: 38096705
Drug: Antibiotic receipt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic receipt per physician discretion (vs for cesarean prophylaxis)
Study: 38096705
Drug: 3 factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 factor model (cesarean birth, receipt of antibiotics per physician discretion, university education)
Study: 38097741
Drug: Olaparib (O)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (O) maintenance therapy
Study: 38098024
Drug: Matched-pair group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched-pair group receiving coated implant
Study: 38098221
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg/day for 3 days and 200 mg/day for 11 days
Study: 38098734
Drug: Digital Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Therapy for Obesity App (DTxO)
Study: 38099081
Drug: Accelerated high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated high-dose theta burst stimulation (ahTBS)
Study: 38099673
Drug: GST-HG171 (150-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST-HG171 (150-900 mg single ascending doses)
Study: 38099673
Drug: GST-HG171 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST-HG171 (150 and 300 mg multiple ascending doses)
Study: 38099673
Drug: GST-HG171/ritonavir (150/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST-HG171/ritonavir (150/100 mg BID for 5 days)
Study: 38099673
Drug: GST-HG171/ritonavir (150/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST-HG171/ritonavir (150/100 mg BID)
Study: 38100078
Drug: Diquafosol Sodium
DrugBank: Diquafosol (DB15919)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Diquafosol Sodium Ophthalmic Solution, dosage and duration not available
Study: 38100110
Drug: Azithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (single dose, biannual administration over 2 years)
Study: 38100110
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, biannual administration over 2 years)
Study: 38100172
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education program including face-to-face counseling on lifestyle modifications, blood pressure monitoring, and medication compliance-related health education during enrollment and monthly follow-ups.
Study: 38100536
Drug: Recombinant vaccinia
Normalized name: Dna (recombinant vaccinia virus strain livp clone gl-onc1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant vaccinia virus expressing Nipah virus glycoprotein (G)
Study: 38100679
Drug: Mepolizumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 300 mg subcutaneously every four weeks
Study: 38101301
Drug: AADvac1 (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: AADvac1 (active immunotherapy against pathological tau protein)
Study: 38101431
Drug: Atezolizumab monotherapy
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab monotherapy (1200 mg IV every 3 weeks)
Study: 38101429
Drug: Lipid-lowering medication
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering medication (LLM) usage
Study: 38101824
Drug: 4-day intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day intensive cognitive behavioural therapy (B4DT)
Study: 38101824
Drug: Individual cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive behavioural therapy (standard CBT)
Study: 38101830
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with deproteinisation using Papacárie Duo
Study: 38101830
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with deproteinisation using 5% sodium hypochlorite solution
Study: 38101840
Drug: Potassium binders
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium binders (PB) treatment for hyperkalaemia (HK)
Study: 38101850
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) programme
Study: 38101851
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) administered at primary motor cortex
Study: 38101851
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) administered at primary sensory cortex
Study: 38101851
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) administered at dorsolateral prefrontal cortex
Study: 38101860
Drug: pTVG-HP (100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: pTVG-HP (100 µg administered intradermally) and nivolumab (240 mg intravenous infusion) every 2 weeks for 3 months, then every 4 weeks for 1 year.
Study: 38101901
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg NLY01
Study: 38101901
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg NLY01
Study: 38102226
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg/d
Study: 39695798
Drug: 7-day antimicrobial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day antimicrobial therapy
Study: 39695798
Drug: 14-day antimicrobial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day antimicrobial therapy
Study: 38102496
Drug: BRIGHT (cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRIGHT (cognitive behavioral therapy)
Study: 38102536
Drug: Supervised concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised concurrent group (SCG, n=30)
Study: 38102544
Drug: Clinical pharmacists'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacists' medication reconciliation
Study: 38102544
Drug: Emergency physicians'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency physicians' medication reconciliation
Study: 38102544
Drug: Clinical pharmacists'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacists' written copy of drug history
Study: 38102544
Drug: Medication discrepancies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication discrepancies detected
Study: 38102544
Drug: Relationship between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relationship between discrepancies and comorbidities/drugs
Study: 38102687
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg methylprednisolone intravenous bolus over 5 minutes
Study: 38103784
Drug: Yoga-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga-based intervention (YBI) with personal practice videos, private sessions, daily text messages, and monetary incentives
Study: 38103842
Drug: Camostat 100
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat 100 mg 3 times daily
Study: 38103842
Drug: Camostat 200
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat 200 mg 3 times daily
Study: 38103842
Drug: Camostat 300
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat 300 mg 3 times daily
Study: 38103947
Drug: Cabozantinib 20
Normalized name: cabozantinib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 20 mg (DL 0) or 40 mg (DL 1) daily on days 1-28 combined with FTD/TPI 35 mg/m².
Study: 38103947
Drug: Cabozantinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib and FTD/TPI combination treatment.
Study: 38103956
Drug: Pencil beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pencil beam scanning proton therapy with a simultaneous integrated boost (SIB) approach and at least 1 rescan evaluation during the first 5 ± 2 fractions.
Study: 38104036
Drug: Imatinib (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (first-line treatment, 69.9% of patients)
Study: 38104036
Drug: General TKI
Approvals — FDA: no, EMA: no, PMDA: no
Description: General TKI treatment adherence
Study: 38104036
Drug: Impact of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact of COVID-19 on treatment
Study: 38104131
Drug: Flutamide (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (administered orally 6-12 hours prior to prostate biopsy)
Study: 38104145
Drug: Proactive opioid-sparing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive opioid-sparing analgesic protocol
Study: 38104538
Drug: Non-anuric participants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anuric participants (cumulative 24 h UO at inclusion ≥0.05 mL kg-1 h-1)
Study: 38104538
Drug: Anuric participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anuric participants (cumulative 24 h UO at inclusion <0.05 mL kg-1 h-1)
Study: 38104569
Drug: guselkumab 200→100
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 200→100 mg
Study: 38104569
Drug: guselkumab 600→200
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 600→200 mg
Study: 38104569
Drug: guselkumab 1200→200
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 1200→200 mg
Study: 38105142
Drug: Sitravatinib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitravatinib (120 mg QD or 100 mg QD) plus Nivolumab (240 mg every 2 weeks or 480 mg every 4 weeks)
Study: 38105505
Drug: Tiragolumab (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab (2, 8, 30, 100, 400, 600, or 1200 mg) followed by atezolizumab (1200 mg)
Study: 38105505
Drug: Tiragolumab (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab (840 mg) followed by atezolizumab (1680 mg)
Study: 38105505
Drug: Tiragolumab (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab (840 mg) plus atezolizumab (1680 mg)
Study: 38105911
Drug: 0.25% reproxalap
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% reproxalap ophthalmic solution
Study: 38106133
Drug: Genotype-driven guidance
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-driven guidance of antiplatelet therapy
Study: 38106555
Drug: Zapnometinib (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zapnometinib (900 mg on Day 1; 600 mg on Days 2-6)
Study: 38106564
Drug: Zotarolimus-eluting drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotarolimus-eluting drug-eluting stent
Study: 38106570
Drug: Iptacopan (10-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iptacopan (10-100 mg for days 1-21, 200 mg for days 22-84)
Study: 38107263
Drug: Early changes
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early changes in sensitive echo indices (e.g., global longitudinal strain) and cardiac biomarkers (e.g., troponin and natriuretic peptides)
Study: 38107263
Drug: Expert consensus-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expert consensus-based strategies in cardiac monitoring and anthracycline dose modification
Study: 38107366
Drug: Postoperative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesic usage
Study: 38107366
Drug: Well-being assessment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Well-being assessment using EQ-5D-5 L
Study: 38107443
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta-1a or peginterferon beta-1a therapy (IFN)
Study: 38107482
Drug: Mg citrate
Normalized name: K-Mg Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg citrate supplementation
Study: 38107641
Drug: Therapeutic Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Chinese massage (TCM) - three weekly 25-min sessions
Study: 38107641
Drug: Placebo massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo massage sessions - three weekly 25-min sessions
Study: 38107829
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy (86.5%, 45/52)
Study: 38107829
Drug: Chemotherapy (83.3%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (83.3%, 40/48)
Study: 38107829
Drug: Capecitabine monotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine monotherapy (62.5%, 25/40)
Study: 38109170
Drug: Technology as
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Technology as an aide to daily self-management.
Study: 38109364
Drug: Rifaximin (antibiotic)
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin (antibiotic)
Study: 38109921
Drug: nOPV2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nOPV2 vaccine administered at a 0.1 mL dose with a 1-week interval (group A)
Study: 38109921
Drug: nOPV2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nOPV2 vaccine administered at a 0.1 mL dose with a 2-week interval (group B)
Study: 38109921
Drug: nOPV2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nOPV2 vaccine administered at a 0.1 mL dose with a 4-week interval (group C)
Study: 38109921
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups after 2 doses of nOPV2
Study: 38109921
Drug: nOPV2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nOPV2 vaccine
Study: 38109916
Drug: BI 690517
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 690517 (aldosterone synthase inhibitor)
Study: 38109984
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg QD
Study: 38109984
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg QD
Study: 38109984
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg QD
Study: 38109984
Drug: Metoprolol 25
Normalized name: metoprolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 25 mg BID
Study: 38110561
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg/day for 21-28 days
Study: 38110665
Drug: Cadonilimab 15
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 15 mg/kg Q3W plus anlotinib
Study: 38110665
Drug: Cadonilimab 10
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 10 mg/kg Q3W plus anlotinib
Study: 38110790
Drug: Minzasolmin (UCB0599);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minzasolmin (UCB0599); orally administered small molecule inhibitor of ASYN misfolding; specific dosage and duration not mentioned.
Study: 38110790
Drug: N-methyl labeled
Normalized name: N-methyl-pyrrolidone
DrugBank: Methyl pyrrolidone (DB12521)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-methyl labeled PET tracer; specific dosage and duration not mentioned.
Study: 38110885
Drug: Sofosbuvir and
Normalized name: sofosbuvir and ledipasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir and daclatasvir treatment
Study: 38110885
Drug: Retesting patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retesting patients who completed treatment 12 months later
Study: 38110901
Drug: HIP1601 (dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIP1601 (dual delayed-release esomeprazole) 40 mg
Study: 38110901
Drug: HGP1705 (delayed-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGP1705 (delayed-release esomeprazole) 40 mg
Study: 38112484
Drug: Semaglutide 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 0.4 mg
Study: 38112645
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids used as an adjunct to antimicrobial therapy for herpetic keratitis
Study: 38112645
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids used as an adjunct to antimicrobial therapy for bacterial keratitis
Study: 38112645
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids for advanced bacterial corneal ulcers
Study: 38112645
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids for fungal keratitis
Study: 38112645
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids for acanthamoeba keratitis
Study: 38112795
Drug: Generic pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Generic pomalidomide (4 mg daily on days 1-21) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22; 20 mg for patients aged > 75 years)
Study: 38112795
Drug: Generic pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Generic pomalidomide plus low-dose dexamethasone
Study: 38113022
Drug: Quantum Molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quantum Molecular Resonance (QMR) treatment, 4 sessions at 1-week intervals.
Study: 38113421
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with maximum tumor RNA disruption index (RDI) values
Study: 38113446
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (2000 IU/day) in participants with <12 ng/mL and denied taking concurrent vitamin D
Study: 38113446
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in participants with <12 ng/mL and denied taking concurrent vitamin D
Study: 38113459
Drug: Parsaclisib 20
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib 20 mg once daily for 8 weeks then 2.5 mg once daily (daily dosing group)
Study: 38113459
Drug: Parsaclisib 20
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group)
Study: 38113470
Drug: venetoclax-R2 (venetoclax
Approvals — FDA: no, EMA: no, PMDA: no
Description: venetoclax-R2 (venetoclax 600 mg daily after ramp-up, lenalidomide 20 mg daily for days 1 to 21, rituximab 375 mg/m2 weekly for 4 weeks then every 8 weeks)
Study: 38114518
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (combined)
Study: 38114624
Drug: CFI-400945 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFI-400945 at doses ranging from 64 mg/day to 128 mg/day
Study: 38114718
Drug: Nucleos(t)ide analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleos(t)ide analogue (NA) therapy cessation
Study: 38114952
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation (AO) therapy
Study: 38114958
Drug: Corega Ultra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corega Ultra denture fixative cream (GlaxoSmithKline)
Study: 38115195
Drug: Nivolumab s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab s.c. 720, 960, or 1,200 mg
Study: 38115195
Drug: Nivolumab i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab i.v. 3 mg/kg every 2 weeks
Study: 38115195
Drug: Nivolumab i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab i.v. 10 mg/kg every 2 weeks
Study: 38115208
Drug: Itacitinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib (300 mg once daily) plus pembrolizumab (200 mg every 3 weeks)
Study: 38115208
Drug: Parsaclisib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib (10 mg once daily in Part 1; 0.3 mg once daily in Part 2) plus pembrolizumab (200 mg every 3 weeks)
Study: 38115209
Drug: Tozorakimab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tozorakimab (subcutaneous or intravenous)